» Articles » PMID: 34984435

Whole Genome Sequencing Assessing Impact of Diabetes Mellitus on Tuberculosis Mutations and Type of Recurrence in India

Abstract

Background: Evidence describing the impact of diabetes mellitus (DM) on the recurrence and mutation rate of Mycobacterium tuberculosis (Mtb) is limited.

Methods: This study was nested in 3 cohort studies of tuberculosis (TB) patients with and without DM in India. Paired Mtb isolates recovered at baseline and treatment failure/recurrence underwent whole genome sequencing. We compared acquisition of single-nucleotide polymorphisms (SNPs), TB drug resistance mutations, and type of recurrence (endogenous reactivation [<8 SNPs] or exogenous reinfection [≥8 SNPs]) by DM status.

Results: Of 1633 enrolled in the 3 parent cohorts, 236 (14.5%) had microbiologically confirmed TB treatment failure/recurrence; 76 Mtb isolate pairs were available for sequencing (22 in TB-DM and 54 in TB-only). The SNP acquisition rate was overall was 0.43 (95% confidence interval [CI], .25-.64) per 1 person-year (PY); 0.77 (95% CI, .40-1.35) per 1 PY, and 0.44 (95% CI, .19-.86) per 1 PY at treatment failure and recurrence, respectively. Significant difference in SNP rates by DM status was seen at recurrence (0.21 [95% CI, .04-.61]) per 1 PY for TB-only vs 1.28 (95% CI, .41-2.98) per 1 PY for TB-DM; P = .02). No significant difference in SNP rates by DM status was observed at treatment failure. Acquired TB drug resistance was seen in 4 of 18 (22%) in TB-DM vs 4 of 45 (9%) in TB-only (P = .21). Thirteen (17%) participants had exogenous reinfection; the reinfection rate at recurrence was 25% (3/12) for TB-DM vs 17% (4/24) in TB-only (P = .66).

Conclusions: Considerable intrahost Mtb mutation rates were present at recurrence among patients with DM in India. One-fourth of patients with DM had exogenous reinfection at recurrence.

Citing Articles

Clinical and Mycobacterium tuberculosis strain characteristics of tuberculosis patients with diabetes mellitus in Changping District, Beijing, China.

Cao X, Song Z, He P, Li X, Lei N, Sun Q BMC Infect Dis. 2025; 25(1):101.

PMID: 39844060 PMC: 11753084. DOI: 10.1186/s12879-025-10470-z.


Characterizing the Etiology of Recurrent Tuberculosis Using Whole Genome Sequencing: Alaska, 2008-2020.

Springer Y, Tompkins M, Newell K, Jones M, Burns S, Chandler B J Infect Dis. 2024; 231(1):94-102.

PMID: 38794931 PMC: 11585661. DOI: 10.1093/infdis/jiae275.


Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges.

Vaishya R, Misra A, Vaish A, Singh S J Diabetes. 2023; 16(5):e13427.

PMID: 37292055 PMC: 11070841. DOI: 10.1111/1753-0407.13427.


Endogenous relapse and exogenous reinfection in recurrent pulmonary tuberculosis: A retrospective study revealed by whole genome sequencing.

He W, Tan Y, Song Z, Liu B, Wang Y, He P Front Microbiol. 2023; 14:1115295.

PMID: 36876077 PMC: 9981662. DOI: 10.3389/fmicb.2023.1115295.

References
1.
Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

2.
Narendran G, Menon P, Venkatesan P, Vijay K, Padmapriyadarsini C, Kumar S . Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis. 2014; 59(12):1798-804. DOI: 10.1093/cid/ciu674. View

3.
Liu Q, Wei J, Li Y, Wang M, Su J, Lu Y . clinical isolates carry mutational signatures of host immune environments. Sci Adv. 2020; 6(22):eaba4901. PMC: 7259932. DOI: 10.1126/sciadv.aba4901. View

4.
Cadena A, Fortune S, Flynn J . Heterogeneity in tuberculosis. Nat Rev Immunol. 2017; 17(11):691-702. PMC: 6247113. DOI: 10.1038/nri.2017.69. View

5.
Sonnenberg P, Murray J, Glynn J, Shearer S, Kambashi B, Godfrey-Faussett P . HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001; 358(9294):1687-93. DOI: 10.1016/S0140-6736(01)06712-5. View